InjectionClinical Overview
Tramadol Hydrochloride Injection (50mg/ml, 100mg/2ml) is an injectable central opioid analgesic on the WHO Model List of Essential Medicines. It binds to mu-opioid receptors and inhibits neuronal reuptake of norepinephrine and serotonin in spinal cord dorsal horn synapses. Indicated for moderate-to-severe acute pain, post-operative surgical pain, renal colic, and severe trauma pain where oral administration is unfeasible.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administer by slow intravenous injection over 2 to 3 minutes, by slow IV infusion, or intramuscularly (50 to 100 mg every 4 to 6 hours, maximum 400 mg daily). Rapid IV push must be strictly avoided as it triggers severe nausea, vomiting, dizziness, and diaphoresis.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, vomiting, dizziness, sedation, dry mouth, sweating, headache. Rare/Severe: Respiratory depression, seizures, severe hypotension/syncope, anaphylaxis, and serotonin syndrome.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Schedule H1 Controlled Substance: Inject slowly IV over 2-3 minutes. High risk of seizures when combined with drugs that lower seizure threshold. Naloxone only partially reverses tramadol toxicity and may increase seizure risk. Strictly avoid in patients with respiratory depression or acute head trauma.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or analgesic treatment guidance. Always consult a registered physician or orthopedic specialist before taking pain relievers, anti-inflammatory medications, or anti-arthritic therapies.
Tramadol HCl Injection 50mg 1 ml
Tramadol Hydrochloride Injection (50mg/ml, 100mg/2ml) is an injectable central opioid analgesic on the WHO Model List of Essential Medicines. It binds to mu-opioid receptors and inhibits neuronal reuptake of norepinephrine and serotonin in spinal cord dorsal horn synapses. Indicated for moderate-to-severe acute pain, post-operative surgical pain, renal colic, and severe trauma pain where oral administration is unfeasible.
Tramadol Tablets 50mg
Tramadol Hydrochloride Tablets (50mg, 100mg Prolonged Release) is an oral centrally acting synthetic atypical opioid analgesic on the WHO Model List of Essential Medicines. It exerts a dual synergistic mechanism: parent drug and its active M1 metabolite bind to mu-opioid receptors, while parent tramadol inhibits reuptake of serotonin and norepinephrine, enhancing descending spinal inhibition. Indicated for management of moderate-to-moderately-severe acute and chronic pain.
Paracetamol 325mg + Tramadol 37.5mg Tablets
Paracetamol (162.5mg/325mg) and Tramadol Hydrochloride (18.75mg/37.5mg) Tablets is a synergistic, multi-mechanistic analgesic combination on the WHO Model List framework for moderate-to-severe pain. Tramadol acts as a weak mu-opioid receptor agonist while simultaneously inhibiting the reuptake of norepinephrine and serotonin (5-HT) in the descending spinal pain inhibitory pathways. Paracetamol acts centrally to inhibit prostaglandin synthesis and activate descending serotonergic pathways. Combining them produces additive analgesia at lower individual doses with faster onset (paracetamol ~30 min) and extended duration (tramadol 6-8 hours). Indicated for management of moderate-to-severe acute pain, postoperative pain, acute musculoskeletal trauma, and severe osteoarthritis flares.
Tramadol Prolonged Release Tablets 100 mg
Tramadol Hydrochloride Tablets (50mg, 100mg Prolonged Release) is an oral centrally acting synthetic atypical opioid analgesic on the WHO Model List of Essential Medicines. It exerts a dual synergistic mechanism: parent drug and its active M1 metabolite bind to mu-opioid receptors, while parent tramadol inhibits reuptake of serotonin and norepinephrine, enhancing descending spinal inhibition. Indicated for management of moderate-to-moderately-severe acute and chronic pain.